1. Home
  2. CHNR vs CMND Comparison

CHNR vs CMND Comparison

Compare CHNR & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Natural Resources Inc.

CHNR

China Natural Resources Inc.

HOLD

Current Price

$3.94

Market Cap

4.7M

ML Signal

HOLD

Logo Clearmind Medicine Inc.

CMND

Clearmind Medicine Inc.

HOLD

Current Price

$2.70

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHNR
CMND
Founded
N/A
2017
Country
China
Canada
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
5.3M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
CHNR
CMND
Price
$3.94
$2.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.1K
22.7M
Earning Date
12-12-2025
01-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.16
$0.07
52 Week High
$8.20
$3.20

Technical Indicators

Market Signals
Indicator
CHNR
CMND
Relative Strength Index (RSI) 45.79 91.22
Support Level $3.75 $0.07
Resistance Level $4.31 $0.13
Average True Range (ATR) 0.27 0.07
MACD 0.10 0.19
Stochastic Oscillator 43.35 82.57

Price Performance

Historical Comparison
CHNR
CMND

About CHNR China Natural Resources Inc.

China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Share on Social Networks: